skip to navigation

PMD Healthcare PMD Healthcare

News

PMD Healthcare Recognizes and Supports Allergy and Asthma Awareness

Share: Share on LinkedIn

ALLENTOWN, Pa.May 17, 2017 /PRNewswire/ — May is Allergy and Asthma Awareness Month, a world-wide education effort to teach families, healthcare professionals, legislators and the media about these chronic illnesses. Asthma alone affects over 25 million Americans and allergies affect another 50 million. Not only do these illnesses interrupt daily life for patients, but they can also be deadly. In fact, there are over 3,000 deaths from asthma every year.

A common misconception is that asthma is just a pediatric disease and patients are able to overcome their symptoms and outgrow the disease itself. Although asthma is the most common chronic pediatric illness in the world, affecting one out of every 10 children, it is not a condition one necessarily outgrows. In fact, many patients with asthma do not develop the condition until they become adults.

“One’s asthma may wax and wane, but if symptoms are ignored lung function will worsen,” said Dr. Michael Blaiss, an advisor to PMD Healthcare, Board certified Allergist/Immunologist and Clinical Professor of Pediatrics at the Medical College of Georgia.

“Meticulous adherence is the best way to treat asthma and that needs buy in by the patient,” adds Blaiss. Home monitoring devices, like Spiro PD, help to actively engage patients and create shared decision making between physicians and patients.

Blaiss and other specialists have lobbied for increased funding for asthma and allergy related programs, better affordability and access to healthcare and continued education about the illnesses. They are pushing for passage of the School-Based Respiratory Health Management Act, granting money to states to fund asthma programs in schools equipped with rescue inhalers.

Founded in 2010, PMD Healthcare is a Medical Device, Digital Health, and Chronic Care Management Service Company with a mission dedicated to creating innovative solutions that empower people to improve their healthcare and quality of life. With that intent focus, PMD developed the first ever personal spirometer, Spiro PD, which was approved by the FDA in 2011.  Since then, Spiro PD has been widely adopted by leading healthcare institutions and has become the standard of care for remote monitoring of lung function for patients who have undergone lung transplant surgery and for patients with cystic fibrosis.

PMD is now launching several new products including its second-generation spirometer, Spiro PD 2.0, and its HIPPA compliant Wellness Management System (WMS). The introduction of the second-generation Spiro PD 2.0 device and HIPPA compliant Wellness Management System (WMS) introduces the use of telemonitoring technology via WIFI to connect patients, providers and caregivers anytime and anywhere.

To learn more about PMD Healthcare, please visit www.MyPMD.com.